Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Reexamination Certificate
2005-06-14
2005-06-14
Spivack, Phyllis (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
C514S449000, C514S184000
Reexamination Certificate
active
06906048
ABSTRACT:
The invention relates to a method for the production of a vascular damaging effect in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of ZD6126 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of one of the following therapies: i) ionizing radiation; ii) a platinum anti-tumor agent; and iii) a taxane. The invention also relates to the use of ZD6126 and one of the above therapies in the manufacture of a medicament for use in the production of a vascular damaging effect in a warm-blooded animal such as a human and to pharmaceutical compositions and kits each comprising ZD6126 and one of a platinum anti-tumor agent and a taxane
REFERENCES:
patent: 2003/0055024 (2003-03-01), Davis
patent: 99/02166 (1999-01-01), None
patent: 99/65515 (1999-12-01), None
patent: 00/48591 (2000-08-01), None
patent: 01/74369 (2001-10-01), None
Blakey et al., “Anti-tumour activity of the novel vascular targeting agent ZD6126 in a human lung tumour xenograft model”, Clin. Cancer Res., CODEN: CCREF ISSN: 1078-0432, vol. 6, (SUPPL. 4522s, Abs. No. 283), Nov., 2000, XP000999407, AstraZeneca, abstract.
Siemann, D.W., “The novel vascular targeting agent ZD6126 enhances the antitumor treatment efficacy of cisplatin and radiotherapy”, Clin. Cancer Res., CODEN: CCREF ISSN: 1078-0432, vol. 6 (SUPPL., 4522s, Abs. No. 284), Nov., 2000, XP000999406, University of Florida, abstract.
Siemann et al., “Targeting tumor blood vessels: An adjuvant strategy for radiation therapy”, Radiotherapy and Oncology, (Oct. 1, 2000), 57/1 (5-12), CODEN: RAONDT ISSN: 067-8140, XP001007731, University of Florida, p. 6, column 2, line 9-line 11, table 1.
Davis et al., “Anti-tumour activity of vascular targeting agent ZD6126 is enhanced by split dosing”, Clinical Cancer Res., CODEN CCREF ISSN: 1078-0432, vol. 6 (SUPPL., 4522s, Abs. No. 282) Nov., 2000, XP000999405, Angiogene Pharmaceuticals, abstract.
Davis Peter David
Dougherty Graeme
AstraZeneca AB
Morgan & Lewis & Bockius, LLP
Spivack Phyllis
LandOfFree
N-acetylcolchinol-O-phosphate combination therapies with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with N-acetylcolchinol-O-phosphate combination therapies with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N-acetylcolchinol-O-phosphate combination therapies with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3477004